By Steve Elliott ~alapoet~ in Medical, News
Monday, December 19, 2011 at 8:00 pm
The exclusive rights to apply the cannabinoids found in marijuana as therapeutic agents awarded by the U.S. federal government to the firm KannaLife only apply to one specific medical condition, KannaLife's CEO told Toke of the Town Monday night.
Dean Petkanas, CEO, KannaLife:
"Our exclusivity is narrowly focused"
(you'd be grinning too!-gfv)
Dean Petkanas, chief executive officer at KannaLife Sciences, told us that the exclusivity applies only for the development and sale of cannabinoid based therapeutics as antioxidants and neuroprotectants for use in the treatment of hepatic encephalopathy.
"It is narrowly defined exclusivity, in that field," Petkanas told us. "Our exclusivity is narrowly focused.">>More
Kannalife: We are a socially responsible, phyto-medical company specializing in the research & development of pharmacological products derived from plants.
Question: If the patent (#6630507) is owned by US DHHS, isn't it really the peoples patent, and why should a for profit company be granted the license to profit from a patent ostensibly owned by the people?
Could it be that the "United States Of America" and the people of the United States of America are now separate and unequal things?